Clinical trial · Observational
Prospective Breast Cancer Biobanking
Prospective Breast Cancer Biobanking Project
NCT04488614CI-TRIAL-00046290PBCBenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A. Early detection of systemic relapses B.Improve adherence and drug monitoring av tamoxifen treatment C. Tumour microenvironment in breast cancer - adipose stromal immune infiltration and interaction with tumour at the growth zone D.Monitor side effects, QoL, depression, fatigue and work life participation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Breast Concervative or Meastectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Early Stage Breast Cancer (Stage I and II)
- description
- Consecutive early stage breast cancer patients who are treated according to the national guidelines. Observation over 11 years.
- interventionNames
- Procedure: Breast Concervative or Meastectomy
Primary outcomes (3)
- measure
- Relapse Free Survival
- timeFrame
- 0-10 years
- description
- Time from operation to relapse of all types
- measure
- Breast Cancer specific Survival
- timeFrame
- 0-10 years
- description
- Time from operation to death due to Breast Cancer
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Early stage Breast Cancer * DCIS gr III Exclusion Criteria: * Not able to read Norwegian * Not able to communicate in Norwegian * Previously diagnosed with cancer * Dementia
References
Publications (1)
- DERIVEDSoiland H, Janssen EAM, Helland T, Eliassen FM, Hagland M, Nordgard O, Lunde S, Lende TH, Sagen JV, Tjensvoll K, Gilje B, Jonsdottir K, Gudlaugsson E, Lode K, Hagen KB, Gripsrud BH, Lind R, Heie A, Aas T, Austdal M, Egeland NG, Bernklev T, Lash TL, Skartveit L, Kroksveen AC, Oltedal S, Kvaloy JT, Lien EA, Sleire L, Mellgren G; PBCB-study group. Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. BMJ Open. 2022 Apr 29;12(4):e054404. doi: 10.1136/bmjopen-2021-054404. PMID 35487718